Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.48 |
| ▸ | BCL2 | P10415 | 3/20 | 0.46 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25245953 | 1.00 | GPR119 (0.48) | GPR119BCL2BCL2L1PIK3CALMNA | |
| SCHEMBL25245955 | 1.00 | GPR119 (0.48) | GPR119BCL2BCL2L1PIK3CALMNA | |
| SCHEMBL25254283 | 0.90 | BCL2 (0.42) | GPR119BCL2BCL2L1 | |
| SCHEMBL19692634 | 0.88 | BCL2 (0.46) | GPR119BCL2BCL2L1TBK1 | |
| SCHEMBL26058355 | 0.79 | BCL2 (0.43) | BCL2BCL2L1 | |
| SCHEMBL23172502 | 0.79 | GPR119 (0.53) | GPR119LMNATP53THRB | |
| SCHEMBL25218941 | 0.79 | SLC6A2 (0.42) | BCL2BCL2L1PIK3CA | |
| SCHEMBL25267346 | 0.79 | SLC6A2 (0.42) | BCL2BCL2L1PIK3CA | |
| SCHEMBL20578235 | 0.78 | BCL2 (0.41) | BCL2BCL2L1TP53 | |
| SCHEMBL21059159 | 0.76 | BCL2 (0.43) | BCL2BCL2L1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271959-A1 | HETEROCYCLIC COMPOUND AS BCL-2 INHIBITOR | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
| EP-4194454-A1 | HETEROCYCLIC COMPOUND AS BCL-2 INHIBITOR | Beijing InnoCare Pharma Tech Co., Ltd. (CN) | 2023-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271959-A1 | HETEROCYCLIC COMPOUND AS BCL-2 INHIBITOR | BCL2, BCL2L11, BCL2L2 | GPR119 1363/4885BCL2 1/4885BCL2L1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.